Puma Biotechnology Financial Statements
NASDAQ: PBYIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Puma Biotechnology revenue and earnings
In fiscal 2025, Puma Biotechnology generated $228.4 million in revenue, down 0.9% from fiscal 2024, its first annual decline since 2024. Net income was $31.1 million (+2.8% year over year), for a net margin of 13.6% versus a median of 0.0% in the prior 5 years. Gross margin was 74.5% (up from 72.1%) and operating margin 16.3%.
Diluted earnings per share came in at $0.61, down from $0.62. Over the last 5 fiscal years, PBYI's revenue has grown at a 0.3% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Puma Biotechnology income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 228.37M | 230.47M | 235.64M | 228.03M | 253.16M | 225.11M | 272.26M | 250.99M | 27.68M | — |
| Revenue growth (YoY) | -0.91% | -2.19% | +3.34% | -9.92% | +12.46% | -17.32% | +8.47% | +806.60% | — | — |
| Cost of Revenue | 58.16M | 64.40M | 62.68M | 55.09M | 63.70M | 39.37M | 36.81M | 34.62M | 5.57M | — |
| Gross Profit | 170.21M | 166.06M | 172.96M | 172.94M | 189.45M | 185.74M | 235.44M | 216.37M | 22.11M | — |
| Operating Expenses | 132.91M | 135.10M | 140.31M | 149.22M | 188.16M | 255.51M | 311.31M | 345.65M | 320.07M | 276.60M |
| Research & Development | 62.07M | 54.94M | 50.38M | 52.24M | 71.87M | 97.65M | 132.85M | 164.85M | 207.81M | 222.80M |
| Selling, General & Admin | 70.85M | 80.16M | 89.93M | 89.98M | 116.29M | 118.49M | 141.64M | 146.17M | 106.69M | 53.80M |
| Operating Income | 37.30M | 30.97M | 32.64M | 23.72M | 1.29M | -30.40M | -39.05M | -94.66M | -292.39M | -276.60M |
| Interest Expense | 6.62M | 12.45M | 13.33M | 11.59M | 12.81M | 14.05M | 15.02M | 10.98M | 720.00K | — |
| Other Income (Expense) | -1.52M | -6.87M | -9.97M | -23.26M | -30.09M | -29.39M | -36.50M | -18.90M | 435.00K | 585.00K |
| Pretax Income | 35.78M | 24.10M | 22.67M | 457.00K | -28.80M | -59.79M | -75.54M | -113.56M | — | — |
| Income Tax | 4.67M | -6.18M | 1.08M | 455.00K | 324.00K | 207.00K | 53.00K | 17.00K | 0 | 0 |
| Net Income | 31.11M | 30.28M | 21.59M | 2.00K | -29.13M | -59.99M | -75.59M | -113.58M | -291.95M | -276.01M |
| Net Income growth (YoY) | +2.75% | +40.23% | +1079450.00% | — | — | — | — | — | — | — |
| EPS (Basic) | 0.62 | 0.62 | 0.46 | 0.00 | -0.72 | -1.52 | -75,595.00 | -2.99 | -7.85 | -8.29 |
| EPS (Diluted) | 0.61 | 0.62 | 0.45 | 0.00 | -0.72 | -1.52 | -1.95 | -2.99 | -7.85 | -8.29 |
| Shares Outstanding (Basic) | 50.01M | 48.65M | 47.13M | 44.67M | 40.64M | 39.58M | 38.77M | 37.94M | 37.17M | 33.30M |
| Shares Outstanding (Diluted) | 50.65M | 49.10M | 47.55M | 44.93M | 40.64M | 39.58M | 38.77M | 37.94M | 37.17M | 33.30M |
| EBITDA | 48.24M | 42.49M | 44.16M | 33.56M | 12.60M | -20.37M | -30.97M | -87.27M | -289.58M | -275.45M |
| Gross Margin | 74.53% | 72.06% | 73.40% | 75.84% | 74.84% | 82.51% | 86.48% | 86.21% | 79.87% | — |
| Operating Margin | 16.33% | 13.44% | 13.85% | 10.40% | 51.00% | -13.51% | -14.34% | -37.71% | -1056.13% | — |
| Net Margin | 13.62% | 13.14% | 9.16% | 0.00% | -11.51% | -26.65% | -27.77% | -45.25% | -1054.56% | — |
This table shows 10 annual periods of Puma Biotechnology's income statement, from FY 2025 back to FY 2016, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow PBYI's reporting calendar. What is a income statement?